Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2024-02-28 Capital/Financing Update
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
Capital/Financing Update Classification · 1% confidence The document is a press release from Nicox SA detailing a debt restructuring agreement, operational cost reductions, and corporate governance changes (board resignations). While it mentions an upcoming Extraordinary General Meeting (EGM), the primary purpose of the document is to announce the terms of the debt restructuring and the resulting strategic changes to the company's operations and capital structure. This fits the definition of a Capital/Financing Update (CAP) as it covers fundraising/financing activities and debt restructuring.
2024-02-28 English
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
Board/Management Information Classification · 1% confidence The document is explicitly titled "Press Release" and announces a significant change in senior management: the appointment of Gavin Spencer as CEO and the end of the mandate of the previous CEO. This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-02-28 English
Gavin Spencer, dirigeant expérimenté du secteur de la biotechnologie, nommé Directeur Général de Nicox
Board/Management Information Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a significant management change: the appointment of Gavin Spencer as CEO and the end of the mandate for the previous CEO. This directly aligns with the definition of Board/Management Information, which covers announcements of changes in senior management. The content focuses entirely on this executive transition, the new CEO's background, and his immediate strategic priorities. This is not an earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), but a specific announcement about management personnel.
2024-02-28 French
Nicox : Contrat de licence avec la société Kowa pour le développement et la commercialisation du NCX 470 au Japon
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces a significant business event: a licensing agreement between Nicox and Kowa for NCX 470 in Japan. It details financial terms (upfront payment, milestones, royalties) and strategic implications. This type of announcement, which is a formal communication to the public and market about a material event, is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to periodic results, but since it's a standalone corporate transaction announcement, RNS is the most appropriate general category for non-standard, material disclosures not covered by specific forms like 10-K or DEF 14A. Given the options, RNS serves as the best fit for a press release detailing a licensing deal, as it is a regulatory disclosure. However, looking closely at the definitions, none perfectly capture a 'Press Release' announcing a licensing deal. The closest categories are ER (Earnings Release - this is not about earnings results) or RNS (Regulatory Filings - general fallback). Since this is a material event disclosure, RNS is the standard classification for such press releases when a more specific category like M&A (TAR) does not apply (this is a license, not a merger/takeover). I will use RNS as the general regulatory announcement fallback.
2024-02-08 French
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press Release" and announces a significant business event: an exclusive license agreement between Nicox and Kowa for NCX 470 development and commercialization in Japan. It details financial terms (€3 million upfront, milestones, royalties) and corporate status updates. This type of announcement, detailing strategic business transactions, partnerships, or material corporate events outside of routine financial reporting (like 10-K or ER), is best classified as a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the focus was purely on the cash infusion. However, since it is a press release announcing a major licensing deal, and there isn't a specific code for 'Partnership Announcement', RNS serves as the most appropriate general regulatory disclosure category for material, non-standard announcements. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Given the nature of the announcement (a material business development disclosed via press release), RNS is the best fit as a broad regulatory disclosure.
2024-02-08 English
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and announces that Nicox will be making presentations at the upcoming ARVO Annual Meeting 2024, detailing the abstract titles, session types (Poster Session), dates, and presenters. This is an announcement about participation in a scientific/investor event, not the release of a formal regulatory report (like 10-K, IR, or ER) or a general regulatory filing (RNS). While it contains some corporate status updates, the primary purpose is to communicate upcoming scientific presentations, which aligns best with an Investor Presentation (IP) or a general announcement. Given the context of presenting research findings at a major industry conference, 'Investor Presentation' (IP) is the most fitting category, as these announcements often serve to update investors on R&D progress. It is not a formal regulatory filing, a financial report, or a management discussion document. FY 2024
2024-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.